GZMO performance.
1. I would guess that some of the recovery was just a recovery. Like for many of the other Biotechs.
2. They were not participating at ASCO. So, there was no room for post-conference disappointments.
3. Perhaps not so important for the share price development, but anyhow. Last week Prohost came out very strongly in their favour (again) in one of their faxes. They rounded it off as follows:
"WE CANNOT TELL IT ALL
Much more remains to be told about GZMO. In the next Fax issue we will talk about the importance of the firm’s SAGE technology and its diagnostic products for the different disciplines of science and medicine. Additionally, we will bring to your attention many more important lucrative agreements that will have an on GZMO’S near-term finances.
We will talk about GZMO’S other cancer treatments, its antisense collaboration with Hybridon, ISIS and other firms.
We will also give you a hint about what you must expect, or not expect, to happen to this firm’s value, near-term and why. And also, how you can feel beforehand that good news is on its way to … GZMO."
Perhaps they are right about forthcoming near-term lucrative developments. And if they know something, someone else should also know at least as much.
Btw. What kind of status does Prohost have? Is it considered a good, a normal or a not very informed newsletter?
Ice |
